AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Evaluate the Safety of Linaclotide in IBS-C Patients in China
- Conditions
- Irritable Bowel Syndrome-IBS
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3028
- Registration Number
- NCT04462900
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
An INternational Frontline Ovarian Cancer Real World Management Study
- Conditions
- Ovarian Neoplasms
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 989
- Registration Number
- NCT04460768
- Locations
- 🇨🇳
Research Site, Taipei City, Taiwan
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
- Conditions
- Small Cell Lung Carcinoma Extensive Disease
- Interventions
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 166
- Registration Number
- NCT04449861
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease
- First Posted Date
- 2020-06-26
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT04449484
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 196
- Registration Number
- NCT04445714
- Locations
- 🇮🇳
Research Site, New Delhi, India
A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers
- Conditions
- PharmacokineticsBioavailability
- Interventions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT04435483
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 205
- Registration Number
- NCT04425200
- Locations
- 🇯🇵
National Hospital Organization Kure Medical Center, Kure, Hiroshima, Japan
🇯🇵Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, Japan
🇯🇵Kanazawa University Hospital, Kanazawa, Ishikawa, Japan
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 267
- Registration Number
- NCT04421963
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC
- Conditions
- Unresectable Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT04416633
- Locations
- 🇮🇳
Research Site, New Delhi, India
A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831
- Conditions
- Cardiovascular Disease
- Interventions
- Drug: 14C]AZD4831 Oral Solution
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT04407091
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom